A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
about
A randomized, double-blind, placebo-controlled, phase III study of the short-acting β1-adrenergic receptor blocker landiolol hydrochloride for coronary computed tomography angiography in Japanese patients with suspected ischemic cardiac disease.Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.
P2860
A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A randomized, double-blind, pl ...... cted ischemic cardiac disease.
@en
A randomized, double-blind, pl ...... cted ischemic cardiac disease.
@nl
type
label
A randomized, double-blind, pl ...... cted ischemic cardiac disease.
@en
A randomized, double-blind, pl ...... cted ischemic cardiac disease.
@nl
prefLabel
A randomized, double-blind, pl ...... cted ischemic cardiac disease.
@en
A randomized, double-blind, pl ...... cted ischemic cardiac disease.
@nl
P2093
P2860
P1476
A randomized, double-blind, pl ...... cted ischemic cardiac disease.
@en
P2093
Akira Yamashina
Kazuhiro Hara
Masaharu Hirano
Masahiro Jinzaki
Misako Iino
Sachio Kuribayashi
Takahiko Suzuki
Takuhiro Yamaguchi
Yuji Ikari
P2860
P2888
P356
10.1007/S10554-013-0253-3
P478
29 Suppl 1
P577
2013-06-20T00:00:00Z